How India Exports Axitinib to the World

Axitinib, marketed under the brand name Inlyta, received FDA approval in January 2012 for the treatment of advanced renal cell carcinoma. As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of axitinib, indicating a competitive generic market. The regulatory pathway for axitinib in the U.S. involves submission of an ANDA demonstrating bioequivalence to the reference listed drug, Inlyta. Notably, there are no current FDA import alerts or restrictions specific to axitinib, facilitating its importation into the U.S. market.

Despite the presence of 56 active Indian exporters of axitinib, the U.S. does not feature among the top five destination countries for Indian exports of this drug. This suggests that while the U.S. market is open to axitinib imports, other markets may be more prominent destinations for Indian exporters.

In February 2011, the European Medicines Agency (EMA) granted orphan designation to axitinib for the treatment of renal-cell carcinoma. However, this designation was later withdrawn. Axitinib is subject to the EU's Good Manufacturing Practice (GMP) requirements, ensuring that imported pharmaceuticals meet stringent quality standards. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) mandates compliance with GMP for all medicinal products. Indian exporters must adhere to these regulations to access the EU and UK markets.

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, axitinib is not included. This exclusion indicates that, while axitinib is recognized for its therapeutic value, it is not considered essential for meeting the priority health care needs of the population on a global scale. Consequently, axitinib is not part of the WHO Prequalification Programme, which focuses on medicines deemed essential. Regarding pharmacopoeia standards, axitinib is listed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), and European Pharmacopoeia (EP), providing standardized quality benchmarks for its production and quality control.

In India, axitinib is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for axitinib, allowing market-driven pricing. For export purposes, Indian pharmaceutical companies must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating the monitoring of pharmaceutical exports.

The primary patent for axitinib has expired, leading to increased generic competition. This expiration has enabled multiple manufacturers to produce and export generic versions of axitinib, contributing to the presence of 56 active Indian exporters and a total export value of $0.1 million USD.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include axitinib, reflecting ongoing evaluations of its global essentiality. (who.int)

In November 2025, the WHO launched a virtual cGMP Training Marathon to enhance manufacturing workforce skills across all regions, aiming to improve compliance with GMP standards among pharmaceutical manufacturers, including those producing axitinib. (who.int)

In December 2025, the WHO issued a Medical Product Alert regarding falsified versions of IBRANCE (palbociclib), highlighting the importance of vigilance against counterfeit oncology drugs, a concern relevant to axitinib manufacturers and exporters. (who.int)

In January 2026, the WHO published the 39th volume of WHO Drug Information, providing updates on pharmaceutical standards and regulations, which are pertinent to axitinib's manufacturing and export processes. (who.int)

In February 2026, the WHO released the report of the 25th Expert Committee on Selection and Use of Essential Medicines, offering insights into the selection criteria and considerations for essential medicines, indirectly impacting the market dynamics of drugs like axitinib. (who.int)

Axitinib, a tyrosine kinase inhibitor used in cancer treatment, is primarily manufactured in India. The production of Active Pharmaceutical Ingredients (APIs) for such drugs often relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have highlighted the vulnerabilities in this supply chain. For instance, in March 2026, the closure of the Strait of Hormuz due to regional conflicts led to significant disruptions in shipping routes, affecting the timely delivery of raw materials and APIs. Such incidents underscore the need for diversification in sourcing strategies to mitigate potential supply chain interruptions.

Our proprietary trade data indicates that the top five exporters of Axitinib from India account for 42.2% of the total export value, with SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED leading at an 11.6% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

The Indian government's Production Linked Incentive (PLI) scheme, initiated in March 2020, aims to boost domestic manufacturing of pharmaceuticals and reduce reliance on imports. While this initiative has encouraged diversification, the current supplier concentration indicates that further efforts are needed to achieve a more balanced supply chain.

The geopolitical landscape significantly impacts the pharmaceutical supply chain. In March 2026, the closure of the Strait of Hormuz due to military conflicts led to a near halt in maritime traffic, disrupting global trade routes. This blockade affected the timely delivery of pharmaceutical products and raw materials, leading to increased costs and potential shortages. According to UNCTAD, such disruptions raise concerns about ripple effects across energy markets, maritime transport, and global supply chains.

Additionally, tensions in the Red Sea and the Strait of Hormuz have led major shipping lines to suspend transits through these critical waterways, further exacerbating supply chain challenges. These disruptions highlight the need for robust risk management strategies to navigate the complexities of global trade routes.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a limited number of exporters.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI scheme to enhance local production capabilities and reduce reliance on imported raw materials.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to circumvent geopolitical hotspots and ensure continuity in supply chains.

• Enhance Inventory Management: Maintain strategic stockpiles of critical raw materials and finished products to buffer against supply disruptions.

• Implement Robust Risk Assessment Protocols: Regularly assess geopolitical developments and their potential impact on the supply chain to proactively address emerging risks.

RISK_LEVEL: MEDIUM